Dose ranges from the published research, in research context only.

Doses from the published studies — not a protocol

There is no FDA-approved dose for BPC-157, no approved dose for TB-500, and no validated dose for the blend as a combination. What the dosage page contains is what the published studies used, in the species and models in which they used it. For BPC-157, the most common rodent regimen is 10 micrograms per kilogram, intraperitoneal, once daily. For thymosin beta-4, human IV trials have used milligrams-per-kilogram ranges that bear no direct relationship to community protocols for the fragment. BPC-157's plasma half-life in animal studies is under 30 minutes. No pharmacokinetic data exist for the TB-500 fragment specifically at research doses. The dosage page reports these figures in their research context. It does not contain a human dosing protocol, because none exists in the controlled literature.

Regulatory baseline

There is no FDA-approved human dose for BPC-157, no FDA-approved human dose for TB-500, and no regulatory status whatsoever for the BPC-157 + TB-500 blend as a combination product. In September 2023, the FDA placed both BPC-157 and TB-500 on its Category 2 list of bulk drug substances of safety concern, effectively disqualifying them from compounding under sections 503A and 503B of the Food, Drug, and Cosmetic Act ^[16].

TB-500 (and any thymosin beta-4 derivative) is prohibited at all times by the World Anti-Doping Agency under category S2 (growth factors). BPC-157 has been listed by WADA under category S0 (non-approved substances) since 2022. A Canadian athlete received a four-year sanction for TB-500 use ^[16].

What follows is a summary of the dose ranges and routes documented in the published preclinical and clinical literature, reported in research context. It is not a recommendation.

BPC-157 — what doses the research used

The most commonly tested rodent intraperitoneal regimen for BPC-157 across the Sikiric-lab tendon, ligament, muscle, and gastrointestinal studies is 10 μg/kg once daily, with parallel arms at 10 ng/kg and occasionally 10 pg/kg to confirm dose responsiveness ^[1][3]. The Achilles detachment study used this dose to produce functional and biomechanical improvements that did not occur spontaneously in controls ^[1]. The gastrocnemius crush study used the same intraperitoneal regimen for 14 days ^[3].

Two other routes have been reported in rodent connective-tissue work:

— Topical — 1.0 μg dissolved per gram of neutral cream, applied to the injury site ^[2].

— Oral / drinking water — approximately 0.16 μg/mL in drinking water, eaten ad libitum ^[2]. BPC-157's reported stability in human gastric juice is what underlies the use of oral administration in preclinical work; whether the same oral bioavailability translates to human pharmacokinetics has not been established.

The 2025 scoping review covered 35 preclinical studies and concluded that the rodent dose range and intraperitoneal route are the dominant pattern in the published BPC-157 literature, with only three small human pilot studies on record ^[16].

TB-500 and thymosin beta-4 — what doses the research used

TB-500 dosing in published research is more heterogeneous than BPC-157 dosing, because most of the data are on full-length thymosin beta-4 rather than the LKKTETQ fragment specifically.

In the rat embolic stroke model, thymosin beta-4 was administered at 6 mg/kg intraperitoneal, first 24 hours after middle-cerebral-artery occlusion and then every three days for four doses ^[11]. In the mouse cardiac repair models, doses of 150 μg per mouse (intraperitoneal) were used for adult epicardial progenitor mobilization and neovascularization, with intracardiac and systemic delivery both reported ^[10]. The 2004 Nature paper describing PINCH / ILK complex formation and Akt activation did not specify a single dose in its abstract; the experimental paper reported both intracardiac and intraperitoneal delivery ^[9].

The human ophthalmic trials of thymosin beta-4 used 0.1% topical solution (RGN-259), dosed five times daily for four weeks (Phase 3 neurotrophic keratopathy) ^[14] or six times daily for 28 days (Phase 2 severe dry eye) ^[15]. The dermal Phase 2 work in pressure ulcers, stasis ulcers, and epidermolysis bullosa used topical formulations in trial; preclinical work has used both topical and subcutaneous routes ^[12].

No published controlled trial has established a human systemic dose for TB-500 or thymosin beta-4. Vendor-published 'protocols' for the synthetic fragment are not derived from controlled human pharmacokinetic data.

Pharmacokinetics and route considerations

BPC-157's plasma half-life in preclinical work is reported as under 30 minutes, with hepatic metabolism and renal clearance ^[16]. Thymosin beta-4 is also short-lived in circulation. The 2025 scoping review identified this short half-life as a key limitation for translational dosing — repeated administration is required to maintain any plasma exposure, and the relevance of brief systemic peaks to the regenerative effects seen in tissue is not fully resolved.

The routes most commonly reported in the published research are intraperitoneal (most rodent studies for both peptides), subcutaneous (vendor-typical research protocols), topical (BPC-157 wound and joint studies; thymosin beta-4 ophthalmic and dermal trials), oral via drinking water (BPC-157 only, rodent), and intracardiac (thymosin beta-4 cardiac models). Whether the local-tissue concentrations achieved in any of these routes translate to a human therapeutic window is not established for either peptide.

BPC-157 is described in the literature as stable in human gastric juice, which is the basis for oral preclinical dosing. TB-500 and thymosin beta-4 are conventionally formulated for parenteral administration; oral bioavailability of the LKKTETQ fragment is not well characterized.

The blend itself

Compounders sell research vials of the BPC-157 + TB-500 blend in two common ratios — 5 mg : 5 mg and 5 mg : 10 mg per vial — but there is no consensus dose because there is no FDA-approved combination product and no controlled in-vivo combination study published in the peer-reviewed literature ^[18]. Any 'protocol' circulating in forum threads or vendor copy for the blend specifically is an extrapolation from the single-agent rodent literature, not a dose validated against the combination.

The most defensible thing to say about the blend's dosing is that the published evidence supports each individual peptide at the doses and routes described above, in the species and models in which it has been studied. The published evidence does not support any specific human regimen for either compound, alone or together.